[18F]SynVest-1
Huntington Disease
Universitaire Ziekenhuizen KU LeuvenN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the Huntington Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deutetrabenazine Teva Branded Pharmaceutical Products R&D LLC | Phase 4 | BBB |
Tetrabenazine William Ondo, MD | Phase 4 | BBB |
ro7234292 Hoffmann-La Roche | Phase 3 | BBB |
Dimebon Medivation, Inc. | Phase 3 | BB |
Pridopidine Prilenia | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →